BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
BioVie Inc. discusses its late-stage drug pipeline in an interview featuring Chairman Terren Peizer, set to air on The RedChip Money Report on June 26, 2021. The company focuses on innovative therapies for liver disease, neurological disorders, and certain cancers. Major highlights include BIV201, which is under investigation for refractory ascites and hepatorenal syndrome, and NE3107, aimed at reducing neuroinflammation and insulin resistance in Alzheimer’s and Parkinson’s diseases. The Phase 3 study for NE3107 is planned for mid-2021.
- BIV201 has FDA Fast Track status and is expected to complete a Phase 2 study by early 2022.
- Plans for a pivotal Phase 3 study of BIV201 for hepatorenal syndrome are set for 2022.
- NE3107 targets Alzheimer’s and Parkinson’s diseases, with an FDA-authorized Phase 3 trial starting in mid-2021.
- Potential risks associated with capital raising and financial limitations may affect future operations.
- Clinical trial outcomes are uncertain, which may impact approval and market entry of drug candidates.
Chairman Terren Peizer discusses BioVie’s late-stage drug pipeline with multiple shots on goal
SANTA MONICA, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced an interview with Terren Peizer, Chairman, that will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on this coming Saturday, June 26th, at 7 p.m. local time in 73 million homes across the United States.
In the exclusive interview, Mr. Peizer discusses the Company’s upcoming milestones, updates on the development of transformative therapies targeting chronic diseases, the company’s late-stage drug pipeline with multiple shots on goal and BioVie’s highly accomplished management team and board of directors.
To view the interview segment, please visit: https://www.youtube.com/watch?v=pl3SK0iEV3k
“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal Phase 3 study of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. In neuro-degenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance. Both are drivers of Alzheimer’s and Parkinson’s diseases. The FDA has authorized a pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimer’s. BioVie is planning to initiate this trial in mid-2021 and targeting primary completion in late 2022. A Phase 2 trial of NE3107 in Parkinson’s Disease is planned for later this year, and related compounds have additional potential to treat certain cancers. NE3107 and related compounds are globally patented, first-in-class molecules. For more information, visit http://www.biovieinc.com.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical trials and to obtain approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
Contact:
INVESTOR RELATIONS:
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
Dave Gentry
CEO
RedChip Companies, Inc.
407-491-4498
www.RedChip.com
FAQ
What are the key products in BioVie’s pipeline as of June 2021?
When is the Phase 3 trial for NE3107 expected to begin?
What is the significance of the FDA Fast Track designation for BIV201?
What conditions does BioVie’s BIV201 target?
